With more Covid-19 cases reported in the first five months of 2021 than in the whole of 2020, the rise of the Delta variant, and the fear that hard-won gains of the last three months are at risk, the ACT-Accelerator has mounted a $7.7bn funding appeal.
The Access to COVID-19 Tools Accelerator (ACT-Accelerator) is a global coalition of organisations developing and deploying the new diagnostics, treatments and vaccines needed to end the acute phase of the pandemic.
The ACT-Accelerator partnership was formed at the onset of the pandemic in response to a call from G20 leaders, and was launched in April 2020. Critical funding for the effort comes from an unprecedented mobilisation of donors, including countries, the private sector, philanthropists and multilateral partners.
... to continue reading you must be subscribed
